BRY812, an anti-LIV-1 antibody drug conjugate with novel conjugation method for cancer therapeutics

被引：0
|
作者：
Zhao, Xiaobei
Zhu, Jie
Zhou, Yaqiong
Li, Jing
Nie, Lei
Wang, Haibin
Chen, Gang
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-1886
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1886
引用
收藏
页数：2
相关论文
共 50 条
  • [1] LIV-1 Antibody-Drug Conjugate: A Novel Therapeutic Agent for Breast Cancer
    Smith, L. M.
    Sussman, D.
    Nesterova, A.
    Westendorf, L.
    Duniho, S.
    Anderson, M.
    Mbow, B.
    Gregoire, A.
    Hunter, J.
    Whiting, N.
    Law, C. L.
    Benjamin, D. R.
    CANCER RESEARCH, 2010, 70
  • [2] Anti-human LIV-1 antibody drug conjugate for treatment of metastatic prostate cancer
    Zhao, Xiaobei
    Chen, Gang
    CANCER RESEARCH, 2023, 83 (11)
  • [3] SGN-LIV1A: A Novel Antibody-Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer
    Sussman, Django
    Smith, Leia M.
    Anderson, Martha E.
    Duniho, Steve
    Hunter, Joshua H.
    Kostner, Heather
    Miyamoto, Jamie B.
    Nesterova, Albina
    Westendorf, Lori
    Van Epps, Heather A.
    Whiting, Nancy
    Benjamin, Dennis R.
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (12) : 2991 - 3000
  • [4] LIV-1 antibody-drug conjugate: A novel therapeutic agent for breast and prostate cancer
    Sussman, Django
    Nesterova, Albina
    Westendorf, Lori
    Duniho, Steven
    Anderson, Martha
    Mbow, Brianna
    Gregoire, Ashley
    Hunter, Joshua H.
    Whiting, Nancy
    Corey, Eva
    Vessella, Robert L.
    Benjamin, Dennis R.
    Smith, Leia M.
    CANCER RESEARCH, 2011, 71
  • [5] SGN-LIV1A: A phase 1 trial evaluating a novel antibody-drug conjugate in patients with LIV-1-positive breast cancer
    Forero, Andres
    Burris, Howard, III
    LoRusso, Patricia
    Specht, Jennifer
    Miller, Kathy
    Mita, Monica
    Liu, Minetta C.
    Modi, Shanu
    Pusztai, Lajos
    Sussman, Django
    Kostic, Ana
    CANCER RESEARCH, 2015, 75
  • [6] SGN-LIV1A, an antibody-drug conjugate (ADC), in patients with LIV-1-positive breast cancer.
    Kostic, Ana
    Anderson, Martha
    Duniho, Steven
    Miyamoto, Jamie
    Nesterova, Albina
    Sussman, Django
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] SGN-LIV1A: a development stage antibody drug-conjugate targeting LIV-1 for the treatment of metastatic breast cancer.
    Sussman, Django
    Smith, Leia M.
    Anderson, Martha E.
    Duniho, Steve
    Hunter, Joshua H.
    Kostner, Heather
    Miyamoto, Jamie B.
    Nesterova, Albina
    Westendorf, Lori
    Van Epps, Heather A.
    Whiting, Nancy
    Benjamin, Dennis R.
    CANCER RESEARCH, 2013, 73 (08)
  • [8] Interim analysis of a phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with metastatic breast cancer
    Forero, A.
    Burris, H., III
    Mita, M.
    Specht, J.
    Weise, A.
    Liu, M. C.
    Modi, S.
    Pusztai, L.
    Kostic, A.
    Yang, J.
    Li, M.
    Hengel, S.
    Miller, K.
    CANCER RESEARCH, 2016, 76
  • [9] Efficacy of Anti-RON Antibody Zt/g4-Drug Maytansinoid Conjugation (Anti-RON ADC) as a Novel Therapeutics for Targeted Colorectal Cancer Therapy
    Feng, Liang
    Yao, Hang-Ping
    Wang, Wei
    Zhou, Yong-Qing
    Zhou, Jianwei
    Zhang, Ruiwen
    Wang, Ming-Hai
    CLINICAL CANCER RESEARCH, 2014, 20 (23) : 6045 - 6058
  • [10] Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily pretreated metastatic breast cancer
    Forero-Torres, A.
    Modi, S.
    Specht, J.
    Miller, K.
    Weise, A.
    Burris, H., III
    Liu, M.
    Krop, I.
    Pusztai, L.
    Kostic, A.
    Li, M.
    Mita, M.
    CANCER RESEARCH, 2017, 77
12345